global
pandem
case
caus
infect
ongo
approv
antivir
intervent
describ
effect
treatment
cohort
confirm
case
wuhan
china
retrospect
studi
adult
hospit
confirm
treat
either
nebul
bid
arbidol
tid
combin
plu
arbidol
serial
test
along
hematolog
measur
includ
cell
count
blood
biochemistri
serum
cytokin
level
temperatur
blood
oxygen
satur
level
record
patient
hospit
stay
treatment
without
arbidol
significantli
reduc
durat
detect
viru
upper
respiratori
tract
parallel
reduc
durat
elev
blood
level
inflammatori
marker
crp
find
suggest
investig
therapi
case
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
decemb
outbreak
pneumonia
report
wuhan
hubei
provinc
china
result
infect
novel
coronaviru
cov
sever
acut
respiratori
syndrom
sar
novel
envelop
betacoronaviru
phylogenet
similar
sarscov
unlik
coronavirus
hcovhku
pathogen
human
associ
mild
clinic
symptom
resembl
sarscov
middl
east
respiratori
syndrom
mer
potenti
caus
sever
diseas
critic
distinct
cov
infect
upper
respiratori
tract
tend
caus
mild
diseas
wherea
cov
infect
upper
lower
respiratori
tract
appear
may
caus
sever
diseas
coronaviru
diseas
covid
diseas
caus
sinc
spread
around
globe
pandem
absenc
vaccin
approv
antivir
number
antivir
current
evalu
therapeut
effect
type
broad
spectrum
antivir
exhibit
direct
inhibitori
effect
viral
replic
support
immun
respons
clear
viru
infect
hydrochlorid
monohydr
broad
spectrum
directact
antivir
induc
ifn
product
phagocyt
activ
arb
display
antivir
activ
respiratori
virus
includ
coronavirus
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
individu
suspect
admit
union
hospit
tongii
medic
colleg
wuhan
china
period
januari
februari
base
initi
symptom
includ
fever
chill
cough
sore
throat
headach
nasal
discharg
myalgia
fatigu
short
breath
andor
diarrhea
retrospect
examin
outcom
patient
laboratori
confirm
receiv
antivir
treatment
either
tianjin
sinobloway
biolog
arbidol
arb
arbidol
hydrochlorid
jiangsu
simcer
pharm
dispers
tablet
combin
plu
arb
discret
treat
physician
accord
current
practic
guidelin
ad
steril
water
introduc
aerosol
use
nebul
mask
treatment
bid
ie
arb
treatment
tablet
tid
ie
addit
confirm
case
wuhan
temporari
shelter
hospit
februari
transfer
union
hospit
treat
arb
also
includ
retrospect
studi
ethic
approv
analysi
data
collect
waiv
hospit
institut
review
board
sinc
patient
data
collect
conform
polici
public
health
outbreak
investig
emerg
infecti
diseas
issu
nation
health
commiss
peopl
republ
china
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
timetovir
clearanc
defin
number
day
elaps
onset
symptom
time
first
two
consecut
neg
pcr
test
least
hour
apart
compar
treatment
group
use
timetoev
analysi
timetovir
clearanc
function
treatment
analyz
use
cox
proport
hazard
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
regress
model
age
code
either
continu
variabl
use
categor
cutoff
either
year
age
includ
covari
time
cours
data
align
date
symptom
onset
aggreg
interv
depend
analyt
account
data
avail
patient
time
point
diseas
cours
interv
analyt
statist
mean
compar
treatment
group
use
analysi
varianc
anova
analys
carri
use
r
version
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
tabl
summar
patient
demograph
clinic
characterist
cohort
case
evalu
retrospect
studi
adult
confirm
admit
union
hospit
wuhan
discret
admit
physician
treat
nebul
figur
patient
show
radiograph
abnorm
chest
comput
tomographi
ct
interpret
local
radiologist
consist
viral
pneumonia
detail
evalu
ct
find
perform
due
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
overwhelm
workload
union
hospit
time
studi
serial
laboratori
measur
blood
level
haemoglobin
glucos
total
bilirubin
direct
bilirubin
alanin
aminotransferas
alt
aspart
aminotransferas
ast
lactat
dehydrogenas
ldh
creatin
kina
ck
blood
urea
nitrogen
bun
albumin
alb
creatinin
troponin
also
conduct
supplementari
appendix
figur
clinic
cours
case
also
assess
relat
age
sex
comorbid
except
haemoglobin
lower
femal
measur
list
found
effect
age
sex
comorbid
diseas
cours
laboratori
measur
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
viral
clearanc
defin
two
consecut
neg
pcr
test
least
hour
apart
previous
describ
figur
notabl
signific
except
crp
diseas
cours
progress
prior
resolut
observ
clear
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
distinct
serum
level
case
treat
ifn
ie
ifn
alon
ifn
arb
case
treat
arb
alon
specif
wherea
circul
level
remain
low
patient
receiv
ifn
receiv
arb
alon
ie
ifn
exhibit
signific
spike
circul
level
figur
figur
also
note
elev
level
crp
approxim
time
elev
supplementari
appendix
figur
similar
crp
also
return
within
normal
rang
diseas
resolv
data
suggest
treatment
ifn
whether
alon
combin
arb
limit
circul
crp
level
figur
sex
comorbid
effect
effect
arb
ifn
treatment
time
viral
clearanc
crp
level
cogniz
arbonli
treatment
group
consist
gener
older
patient
adjust
age
statist
analys
regardless
whether
age
consid
continu
variabl
categor
variabl
yr
vs
yr
yr
vs
yr
effect
ifn
treatment
crp
time
viral
clearanc
remain
statist
signific
case
treat
arb
alon
level
significantli
higher
treat
ifn
day
x
similarli
arb
alon
treatment
group
crp
level
significantli
higher
case
treat
ifn
day
time
viral
clearanc
significantli
shorter
case
treat
compar
treat
arb
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
retrospect
studi
provid
sever
import
novel
insight
diseas
importantli
therapi
appear
shorten
durat
viral
shed
notabl
reduct
marker
acut
inflamm
crp
correl
shorten
viral
shed
suggest
act
along
function
causeeffect
chain
viral
induc
inflamm
repres
pathophysiolog
driver
taken
togeth
find
elev
biolog
plausibl
repres
therapi
diseas
pandem
take
everincreas
toll
urgent
search
effect
prophylact
therapeut
intervent
rapidli
acceler
includ
lopinavirritonavir
chloroquin
remdesivir
well
interferon
ifn
arbidol
arb
combin
antivir
vitro
data
support
consider
coronaviru
target
prior
clinic
test
unfortun
surpris
high
chanc
failur
howev
shown
outbreak
canada
treatment
could
hasten
resolut
coronavirusmedi
human
diseas
prompt
us
evalu
therapi
administ
diseas
earli
stage
outbreak
wuhan
hubei
provinc
china
inde
analysi
suggest
inhal
acceler
viral
clearanc
respiratori
tract
hasten
resolut
system
inflammatori
process
compar
arb
treatment
alon
recogn
data
best
suggest
given
urgenc
find
indic
followup
random
placebo
control
clinic
trial
rct
warrant
success
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
could
benefit
individu
infect
patient
reduc
durat
viral
shed
even
moder
case
cohort
assist
slow
popul
spread
reduct
inflammatori
biomark
follow
inhal
therapi
support
clinic
relev
impact
approach
also
hint
like
function
connect
viral
infect
host
end
organ
damag
shown
provid
prognost
valu
acut
respiratori
distress
syndrom
ard
sever
form
diseas
inde
case
target
intervent
receptor
inhibitor
eg
toclizumab
sarilumab
toward
axi
may
prove
use
therapeut
adjunct
least
sever
ill
form
therapi
recent
approv
china
nation
health
commiss
current
consider
italian
medic
agenc
advantag
block
rest
ifn
target
caus
symptom
retrospect
studi
sever
signific
limit
obviou
fact
studi
cohort
small
nonrandom
unbalanc
demograph
treatment
arm
unequ
size
howev
consid
exploratori
studi
object
determin
rapid
manner
possibl
full
trial
consid
result
indic
rct
warrant
furthermor
sinc
entir
cohort
consist
moder
case
diseas
find
may
indic
occur
sever
ill
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
caution
generaliz
inde
support
lack
impact
age
sex
comorbid
cours
diseas
cohort
shown
influenc
clinic
cours
irrespect
signific
limit
knowledg
find
present
first
suggest
therapeut
efficaci
diseas
avail
antivir
intervent
furthermor
beyond
clinic
benefit
individu
patient
treatment
may
also
benefit
public
health
measur
aim
slow
tide
pandem
durat
viral
shed
appear
shorten
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
qz
respons
patient
care
treatment
clinic
oversight
clinic
data
collect
vc
cp
analys
data
gener
figur
xsw
xx
xw
zhw
collect
laboratori
radiograph
data
sjt
analys
data
trk
enf
conduct
data
analysi
data
interpret
literatur
search
manuscript
write
declar
compet
interest
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
patient
figur
serial
sampl
assess
panel
creactiv
protein
crp
panel
b
day
symptom
onset
valu
record
aggreg
across
day
interv
shown
mean
se
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
